Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Emerging strategies in peripheral T-cell lymphoma
Neha Mehta-Shah
Section of Medical Oncology
Institute of Clinical and Translational Sciences (ICTS)
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging strategies in peripheral T-cell lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Peripheral T-cell Lymphoma
100%
Brentuximab Vedotin
40%
Treatment Options
20%
Novel Treatments
20%
Chemosensitive
20%
Clinical Trials
20%
Patient-derived Xenograft
20%
Gene Expression Profiling
20%
B Cells
20%
Disease Modeling
20%
Targeted Therapy
20%
Response to Therapy
20%
Lymphoma
20%
Rare Diseases
20%
Histone Deacetylase Inhibitor (HDACi)
20%
Effective Therapy
20%
Tyrosine Kinase Inhibitor
20%
Targeted Agents
20%
Disease-based
20%
Spleen
20%
Chemotherapy Regimen
20%
Personalized Approach
20%
Minimal Residual Disease
20%
Response Mechanism
20%
Phosphatidylinositol 3-kinase Inhibitor
20%
CD30
20%
Resistance to Therapy
20%
Resistance Mechanisms
20%
Heterogenous Groups
20%
Therapeutic Advances
20%
Disease Evaluation
20%
Combination Strategy
20%
Subtype Classification
20%
Overall Survival Benefit
20%
Aggressive non-Hodgkin Lymphoma
20%
Targeted Development
20%
Upfront Chemotherapy
20%
Janus Kinase Inhibitors
20%
Medicine and Dentistry
Peripheral T-Cell Lymphoma
100%
Brentuximab Vedotin
40%
Diseases
40%
Gene Expression Profiling
20%
Clinical Trial
20%
B Cell
20%
Overall Survival
20%
Targeted Therapy
20%
Non-Hodgkin Lymphoma
20%
Histone Deacetylase Inhibitor
20%
Rare Disease
20%
Xenograft
20%
Minimal Residual Disease
20%
Tyrosine-Kinase Inhibitor
20%
Janus Kinase Inhibitor
20%
Phosphoinositide 3-Kinase Inhibitor
20%
Chemotherapy
20%